Synthesis of new N,N'-bis(5-arylidene-4-oxo- 4,5-dihydrothiazolin-2-yl)piperazine derivatives under microwave irradiation and preliminary biological evaluation

Scientia Pharmaceutica

Volumn 80, Issue 4, 2012, Pages 825-836

  Coulibaly, Wacothon Karime ^a,b   Paquin, Ludovic ^a   Bénié, Anoubilé ^b   Bekro, Yves Alain ^b   Durieux, Emilie ^c   Meijer, Laurent ^d   Le Guével, Rémy ^a   Corlu, Anne ^a   Bazureau, Jean Pierre ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ NANGUI ABROGOUA   (Côte d’Ivoire)

^c STATION BIOLOGIQUE   (France)

^d Centre de Perharidy   (France)

Author keywords

2,2 (piperazine 1; 4 diyl)bis(5 benzylidene 1,3 thiazol 4(5h) one); 5 arylidene rhodanine; Cytotoxity; Diamines; Microwave irradiation; Protein kinase

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; N N' BIS(5 ARYLIDENE 4 OXO 4 5 DIHYDROTHIAZOLIN 2 YL)PIPERAZINE; PIPERAZINE DERIVATIVE; PROTEIN KINASE; RHODANINE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CRYSTALLIZATION; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MASS SPECTROMETRY; MICROWAVE IRRADIATION; NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY;

EID: 84870883504     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1206-04     Document Type: Article

References (21)

1. Mentgen T, Steuer C, Klein CD. Privileged Scaffolds or Promiscuous Binders: A comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry. J Med Chem. 2012; 55: 743-753. http://dx.doi.org/10.1021/jm201243p
2. Nasr M.N.A., Said S-A. Novel 3,3a,4,5,6,7-Hexahydroindazole and Arylthiazolylpyrazoline derivatives as Anti-inflammatory Agents. Arch Pharm. 2003; 336: 551-559. http://dx.doi.org/10.1002/ardp.200300796
3. Hu Y, Helm J-S, Chen L, Ginsberg C, Gross B, Kraybill B, Tiyanont K, Fang X, Wu T, Walker S. Identification of selective inhibitors for the glycosyltransferase MurG via high-throughput screening. Chem Biol. 2004; 11: 703-711. http://dx.doi.org/10.1016/j.chembiol.2004.02.024
4. Martin L, Rabasseda X, Castaner J. Darbufelone Mesilate. Drugs Future. 1999; 24: 853-857. http://dx.doi.org/10.1358/dof.1999.024.08.534526
5. Johnson A-R, Marletta M-A, Dyer R-D. Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol. Biochemistry 2001; 40: 7736-7745. http://dx.doi.org/10.1021/bi002343f
6. Inagaki M, Tsuri T, Jyoyama H, Ono T, Yamada K, Kobayashi M, Hori Y, Arumura A, Yasui K, Ohno K, Kakudo S, Koizumi K, Suzuki R, Kato M, Kawai S, Matsumoto S. Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (γ-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. J Med Chem. 2000; 43: 2040-2048. http://dx.doi.org/10.1021/jm9906015
7. Teraishi F, Wu S, Zhang L, Guo W, Davis J-J, Dong F, Fang B. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. Cancer Res. 2005; 65: 6380-6387. http://dx.doi.org/10.1158/0008-5472.CAN-05-0575
8. Cutshall N-S, O'Day C, Prezhdo M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg Med Chem Lett. 2005; 15: 3374-3382 http://dx.doi.org/10.1016/j.bmcl.2005.05.034
9. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyata T, Nakoshima M, Yoshimura I, Sakamoto N, Shigeta Y. Long-Term clinical effects of Epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: The 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care. 2006; 29: 1538-1541. http://dx.doi.org/10.2337/dc05-2370
10. Zhang J, Yang P-L, Gray N-S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009; 9: 28-39. http://dx.doi.org/10.1038/nrc2559
11. Galons H, Oumata N, Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Exp Opin Ther Patents. 2010, 20: 377-404. http://dx.doi.org/10.1517/13543770903524284
12. Druker B-J, Talpaz M, Resta D-J, Peng B, Buchdunger E, Ford J-M, Lydon, N-B, Kantarjian H, Capdeville R, Ohnojones S, C.L. Sawyers C-L. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Engl J Med. 2001; 344: 1031-1037. http://dx.doi.org/10.1056/NEJM200104053441401
13. Bazureau J-P, Draye M; eds. Ultrasound and Microwave: Recent advances in organic chemistry. Transworld Research Signpost, Kerala, 2011. ISBN: 978-81-7895-532-2
14. Guihéneuf S, Paquin L, Carreaux F, Durieu E, Meijer L, Bazureau J-P. An efficient approach to dispacamide A and its derivatives. Org Biomol Chem. 2012; 10: 978-987. http://dx.doi.org/10.1039/c1ob06161e
15. Bourahla K, Derdour A, Rahmouni M, Carreaux F, Bazureau J-P. A practical access to novel 2-amino-5-arylidene-1,3-thiazol-4(5H)-ones via sulfur/nitrogen displacement under solvent-free microwave irradiation. Tetrahedron Lett. 2007, 48: 5785-5789. http://dx.doi.org/10.1016/j.tetlet.2007.06.078
16. Kimura R, Kamino, K, Yamamoto M, Nuripa A, Kida T, Kazui H, Hashimoto R, Tanaka T, Kudo T, Yamagata H, Tabara Y, Miki T, Akatsu H, Kosaka K, Funakoshi E, Nishitomi K, Sakaguchi G, Kato A, Hattori H, Uema T, Takeda M. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet. 2007; 16: 15-23. http://dx.doi.org/10.1093/hmg/ddl437
17. Debdab M, Carreaux F, Renault S, Soundararajan M, Federov O, Lozach O, Babault L, Baratte B, Ogawa Y, Hagiwara M, Einsenreich A, Rauch U, Knapp S, Meijer L, Bazureau J-P. Design, synthesis and biological evaluation of leucettines, a class of potent CLK and DYRK kinases inhibitors derived from the marine sponge leucettamine B. Modulation of alternative RNA splicing. J Med Chem. 2011; 54: 4172-4186. http://dx.doi.org/10.1021/jm200274d
18. Besyadetskaya EI, Kuz'min Y. Synthesis and properties of bicyclic compounds containing piperazine and thiazolidine rings Farmatsevt Zhurnal (Kiev). 1973; 28: 34-36.
19. Besyadetskaya EI. Synthesis of 5-substituted N,N-bis(2-thiazolidin-4-one-2-yl)piperazines Farmatsevt Zhurnal (Kiev). 1972; 27: 30-32.
20. Primot A, Baratte B, Gompel M, Borgne A, Liabeuf S, Romette J-L, Costantini F, Meijer L. Purification of GSK-3 by affinity chromatography on immobilised axin. Protein Expression Purif. 2000; 20: 394-404. http://dx.doi.org/10.1006/prep.2000.1321
21. Nakabayashi H, Taketssa K, Miyano K, Yamane T, Sato J. Growth of Human Hepatoma Cell Lines with Differentiated Functions in Chemically Defined Medium Cancer Res. 1982; 42: 3858-3863. http://www.ncbi.nlm.nih.gov/pubmed/6286115